The Treatment Continuity Act of 2025 aims to enhance treatment options for individuals with substance use disorders and serious mental illnesses by amending the Public Health Service Act. This legislation specifically authorizes the Secretary of Health and Human Services to address these conditions through the provision of FDA-approved long-acting injectable medications . Beyond medication, the bill also supports comprehensive care by including provisions for lab testing and supportive counseling for both substance use disorders and serious mental illnesses. Furthermore, it mandates training on the effective use of these long-acting injectable medications in conjunction with associated clinical services. The Act requires an annual report to Congress detailing the program's outcomes and progress in meeting treatment requirements, ensuring accountability and oversight.